Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

ImmuPharma plc. (12/19/19). "Press Release: ImmuPharma Lists on Euronext Growth Brussels". Brussels.

Region Region Brussels
  Country Belgium
Organisations Organisation ImmuPharma plc (LSE: IMM)
  Group ImmuPharma (Group)
  Organisation 2 Euronext Brussels
  Group Euronext (Group)
Products Product Lupuzor™
  Product 2 financial services
Person Person Dimitriou, Dimitri F. (ImmuPharma 201912 CEO)

Through this dual listing, ImmuPharma, which is already listed on AIM, aims to diversify and enlarge its shareholder base in Continental Europe

ImmuPharma PLC, (LSE AIM: IMM – Euronext Growth: ALIMM) a specialist drug discovery and development company, today began trading on Euronext Growth Brussels. On the day of listing in Brussels, ImmuPharma’s market capitalisation stood at approx. €33.37 million. The Company did not issue any new shares.

ImmuPharma is headquartered in London and has its research operations in France and Switzerland. The Company is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by high unmet medical need, low marketing costs and relatively low development costs.

The dual listing on Euronext aims to further increase the visibility of ImmuPharma’s shares in Continental Europe and with European investors. This follows the Company’s recent deal with US Avion Pharmaceuticals, who are now funding an international Phase III trial for its lead programme, Lupuzor™.

Euronext Growth, Euronext’s pan-European MTF dedicated to small & mid-caps, recently obtained the EU SME Growth Market status, which facilitates access to capital markets for European SMEs. The companies listed on Euronext Growth now benefit from simplified market processes in two key legislations: the Prospectus Regulation and the Market Abuse Regulation (MAR). Those evolutions are first steps to additional alleviations and benefits expected to be implemented in the years to come for SME Growth Markets.

Dimitri Dimitriou, ImmuPharma’s CEO, commented: “We are delighted to today’s commencement of ImmuPharma’s shares being traded on Euronext Growth Brussels. We have been planning this dual listing for a while. With us recently successfully completing a significant corporate deal on our most advanced drug in development, Lupuzor™, with our US partner, Avion Pharmaceuticals, the timing is appropriate. Euronext is positioned as the number 1 European Stock Exchange for Life Sciences and Brussels is the hub of an ecosystem in the Life Science sector which is knowledgeable, supportive and attractive to a company like ImmuPharma. We would like to specifically thank the Euronext team and our advisors for their invaluable support through this process.”


To celebrate ImmuPharma’s first trading day on Euronext, Dimitri Dimitriou, ImmuPharma’s Chief Executive Officer, rang the opening bell in Brussels.


Pascal Brabant (Euronext): +32 2 620 15 50

ImmuPharma PLC (

Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 29 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US. For additional information about ImmuPharma please visit

Record changed: 2021-02-08


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for ImmuPharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top